FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1978103469> ?p ?o ?g. }

• W1978103469 endingPage "339" @default.
• W1978103469 startingPage "332" @default.
• W1978103469 abstract "This phase Ib trial assessed safety, tolerability, and maximum tolerated dose (MTD) of figitumumab (CP-751,871), a fully human monoclonal antibody targeting the insulin-like growth factor type 1 receptor (IGF-IR), in combination with docetaxel. Patients with advanced solid tumours were treated with escalating dose levels of figitumumab plus 75 mg m–2 docetaxel every 21 days. Safety, efficacy, pharmacokinetics (PKs), and biomarker responses were evaluated. In 46 patients, no dose-limiting toxicities were attributable to the treatment combination. Grade 3 and 4 toxicities included neutropaenia (n=28), febrile neutropaenia (n=11), fatigue (n=10), leukopaenia (n=7), diarrhoea (n=5), hyperglycaemia, lymphopaenia, cellulitis, DVT, and pain (all n=1). The MTD was not reached. Four partial responses were observed; 12 patients had disease stabilisation of ⩾6 months. Pharmacokinetic and biomarker analyses showed a dose-dependent increase in plasma exposure, and complete sIGF-IR downregulation at doses of ⩾3 mg kg–1. Pharmacokinetics of docetaxel in combination was similar to when given alone. Out of 18 castration-resistant prostate cancer patients, 10 (56%) had ⩾5 circulating tumour cells (CTCs) per 7.5 ml of blood at baseline: 6 out of 10 (60%) had a decline from ⩾5 to <5 CTCs and 9 out of 10 (90%) had a ⩾30% decline in CTCs after therapy. Figitumumab and docetaxel in combination are well tolerated. Further evaluation is warranted." @default.
• W1978103469 created "2016-06-24" @default.
• W1978103469 creator A5006429014 @default.
• W1978103469 creator A5008444865 @default.
• W1978103469 creator A5013567386 @default.
• W1978103469 creator A5013897432 @default.
• W1978103469 creator A5017949156 @default.
• W1978103469 creator A5021891844 @default.
• W1978103469 creator A5024095268 @default.
• W1978103469 creator A5034625178 @default.
• W1978103469 creator A5034748028 @default.
• W1978103469 creator A5043693897 @default.
• W1978103469 creator A5044542632 @default.
• W1978103469 creator A5047198395 @default.
• W1978103469 creator A5051809103 @default.
• W1978103469 creator A5056423529 @default.
• W1978103469 creator A5065158517 @default.
• W1978103469 creator A5068368047 @default.
• W1978103469 creator A5072116005 @default.
• W1978103469 creator A5072378199 @default.
• W1978103469 date "2010-07-01" @default.
• W1978103469 modified "2023-10-13" @default.
• W1978103469 title "The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study" @default.
• W1978103469 cites W1982619307 @default.
• W1978103469 cites W1995594030 @default.
• W1978103469 cites W2016767122 @default.
• W1978103469 cites W2040104879 @default.
• W1978103469 cites W2051839343 @default.
• W1978103469 cites W2085520215 @default.
• W1978103469 cites W2089171551 @default.
• W1978103469 cites W2102995080 @default.
• W1978103469 cites W2112474467 @default.
• W1978103469 cites W2112564453 @default.
• W1978103469 cites W2116483002 @default.
• W1978103469 cites W2117350664 @default.
• W1978103469 cites W2121520362 @default.
• W1978103469 cites W2136137911 @default.
• W1978103469 cites W2147909933 @default.
• W1978103469 cites W2148998801 @default.
• W1978103469 cites W2150863963 @default.
• W1978103469 cites W2161513275 @default.
• W1978103469 cites W2167156722 @default.
• W1978103469 cites W2502670554 @default.
• W1978103469 doi "https://doi.org/10.1038/sj.bjc.6605767" @default.
• W1978103469 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2920021" @default.
• W1978103469 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20628389" @default.
• W1978103469 hasPublicationYear "2010" @default.
• W1978103469 type Work @default.
• W1978103469 sameAs 1978103469 @default.
• W1978103469 citedByCount "78" @default.
• W1978103469 countsByYear W19781034692012 @default.
• W1978103469 countsByYear W19781034692013 @default.
• W1978103469 countsByYear W19781034692014 @default.
• W1978103469 countsByYear W19781034692015 @default.
• W1978103469 countsByYear W19781034692016 @default.
• W1978103469 countsByYear W19781034692017 @default.
• W1978103469 countsByYear W19781034692018 @default.
• W1978103469 countsByYear W19781034692019 @default.
• W1978103469 countsByYear W19781034692020 @default.
• W1978103469 countsByYear W19781034692022 @default.
• W1978103469 crossrefType "journal-article" @default.
• W1978103469 hasAuthorship W1978103469A5006429014 @default.
• W1978103469 hasAuthorship W1978103469A5008444865 @default.
• W1978103469 hasAuthorship W1978103469A5013567386 @default.
• W1978103469 hasAuthorship W1978103469A5013897432 @default.
• W1978103469 hasAuthorship W1978103469A5017949156 @default.
• W1978103469 hasAuthorship W1978103469A5021891844 @default.
• W1978103469 hasAuthorship W1978103469A5024095268 @default.
• W1978103469 hasAuthorship W1978103469A5034625178 @default.
• W1978103469 hasAuthorship W1978103469A5034748028 @default.
• W1978103469 hasAuthorship W1978103469A5043693897 @default.
• W1978103469 hasAuthorship W1978103469A5044542632 @default.
• W1978103469 hasAuthorship W1978103469A5047198395 @default.
• W1978103469 hasAuthorship W1978103469A5051809103 @default.
• W1978103469 hasAuthorship W1978103469A5056423529 @default.
• W1978103469 hasAuthorship W1978103469A5065158517 @default.
• W1978103469 hasAuthorship W1978103469A5068368047 @default.
• W1978103469 hasAuthorship W1978103469A5072116005 @default.
• W1978103469 hasAuthorship W1978103469A5072378199 @default.
• W1978103469 hasBestOaLocation W19781034691 @default.
• W1978103469 hasConcept C112705442 @default.
• W1978103469 hasConcept C121608353 @default.
• W1978103469 hasConcept C126322002 @default.
• W1978103469 hasConcept C126894567 @default.
• W1978103469 hasConcept C143998085 @default.
• W1978103469 hasConcept C197934379 @default.
• W1978103469 hasConcept C2776694085 @default.
• W1978103469 hasConcept C2778375690 @default.
• W1978103469 hasConcept C2779984678 @default.
• W1978103469 hasConcept C2780192828 @default.
• W1978103469 hasConcept C2781190966 @default.
• W1978103469 hasConcept C31760486 @default.
• W1978103469 hasConcept C71924100 @default.
• W1978103469 hasConcept C90924648 @default.
• W1978103469 hasConcept C98274493 @default.
• W1978103469 hasConceptScore W1978103469C112705442 @default.
• W1978103469 hasConceptScore W1978103469C121608353 @default.
• W1978103469 hasConceptScore W1978103469C126322002 @default.

• next